Sign Up
Ready to replace complexity with clarity?
Answer your real world compliance questions (limited time) and save thousands in legal fees and avoided fines.
Automate Compliance TodayUS states A to Z: marijuana, THCA, delta-8, delta-9, delta-10, HHC
State-by-state mapMost read countries: marijuana, CBD and hemp status
All countries on the globeSubstances: status in every state for each one
Compare all substancesFederal hemp redefinition: P.L. 119-103, div. B, sec. 2019
Nov 12, 2026
Applies only to cannabinoids the plant cannot naturally produce.
Dec 11, 2026
The total-THC test, the 0.4 mg per container cap and the exclusion of converted cannabinoids start.
Latest regulatory actions, updated daily
All regulatory actionsHeadlines and the first four sentences are free. Full write-ups, impact reasoning and the archive are for members.
Member · $99/mo
Every rule change, the day it is made.
The price will rise. Join now and $99 a month stays your rate for life.
Become a memberOr read free: every action opens 30 days after it is published. Sign in with email
By topic
Licensing and permitsPackaging and labelingLab testing and QARetail complianceAdvertising and marketingBanking and paymentsTaxesShipping and logisticsTravel and transportLitigationSOPsFor your role
Regulators and agenciesBrands and operatorsRetailers and smoke shopsCultivatorsProcessorsLawyers and complianceInvestorsConsumers and travelersThe Regulator Brief · newsletter
Every rule change that matters, every Monday.
Free: the Monday brief, and every action 30 days after it is published.
Members: the paid weekly, daily alerts and every write-up.
Read by regulators, operators, lawyers and founders.
Cannabis lawyers
Licensed by state. Listings are not endorsements.
By state
Software and services
Compared by fit, never ranked.
Categories
For companies and firms
Be the listing operators and regulators find.
Software and services
Verified, $49/mo: domain-verified badge, your website link, a quote.
Featured, from $399/mo: labeled Featured in your category, monthly release notes.
Lawyers and firms
Claimed, $75/yr: Claimed badge and your firm's website link.
Featured, $199/mo: labeled Featured on your profile.
Claim your companyClaim a lawyer listingPlacements, flat monthly fee
State and country page sponsorshipsExclusive slot on a legality page and its postsRegulator Brief sponsorshipPresenting sponsor or mid-issue banner, free editionMember brief sponsor slotThe paid weekly, read by members onlyFeatured directory placementLabeled Featured in a software categoryCategory sponsorshipOwn one directory category across the sitePaid guest postsLabeled Paid guest post, sponsored linksWrite and partner
Pitch a paid guest postRead guest postsBecome an affiliateSend a tip or correctionContact the teamWho reads it
Regulators at federal, state and county agencies, plus the operators, lawyers and founders they regulate.
Get the media kitSee open placementsSubstances
US states, map and A to ZCountriesFederal hemp 2026: Nov 12 and Dec 11Compound index, every stateTravelling with cannabis or hempMembers get the daily alert email and every full write-up the morning it is published. Every action is free to read 30 days later.
For your role
All news and analysisGuidesAnalysisFAQsTemplates and SOPsCourt filing recapsNews by state and countrySoftware and services: Verified $49/mo, Featured from $399/mo. Lawyers and firms: Claimed $75/yr, Featured $199/mo. Listings are not endorsements.
Regulatory journalism, not legal advice. How we report

The U.S. Supreme Court’s 2024 decisions in Loper Bright Enterprises v. Raimondo and Corner Post, Inc. v. Board of Governors dramatically upended the regulatory landscape for cannabis and hemp stakeholders in 2025 and beyond. By overturning the forty-year-old Chevron deference doctrine and broadening who can bring Administrative Procedure Act (APA) challenges, the Court has exposed the FDA and DEA to stricter judicial scrutiny—particularly in areas of statutory ambiguity that have long defined the rules for products like hemp-derived CBD, cannabinoids, and synthetic derivatives. In an era already shaped by federal rescheduling debates and a new Farm Bill on the horizon, these rulings make the next two years a high-stakes period for regulated cannabis and hemp business owners, compliance officers, investors, and policymakers.
The Supreme Court’s decision in Loper Bright did away with the principle that courts must defer to agencies’ reasonable interpretations of ambiguous statutes. Now, when the FDA or DEA interprets a vague provision of the Food, Drug, and Cosmetic Act or the Controlled Substances Act (CSA), courts apply independent judgment:
For the cannabis and hemp sector, where Congress has repeatedly left gray areas (e.g., the legal status of different cannabinoids, “synthetic” vs. “naturally derived” compounds, or the status of CBD in food and supplements), this marks a watershed moment.
In Corner Post, the Court ruled that the six-year APA statute of limitations to challenge a regulation begins to run not when the rule is issued, but when a specific plaintiff is first injured by that rule (read Supreme Court opinion). This means:
This dramatically increases both agency exposure and business opportunity to reshape the rules.
The FDA has asserted that CBD cannot be sold as a dietary supplement or added to foods, citing its prior investigation as a drug (Epidiolex). Yet, clear statutory text is lacking; Congress never unambiguously prohibited hemp-derived cannabinoids in supplements or food after the 2018 Farm Bill.
FDA ambiguity around intoxicating hemp-derived cannabinoids (e.g., Delta-8 THC) in foods, beverages, and supplements remains hotly contested. With Loper Bright, new players can challenge restrictive or inconsistent FDA guidance, especially in the absence of formal rulemaking.
Courts may now weigh how the FDA interprets “synthetic” cannabinoids—particularly when that term is undefined in federal law—and whether the application of old rules to novel technologies (e.g., biosynthetics, isomerization) is justified.
The DEA’s interpretation of the 2018 Farm Bill has been a flashpoint for conflict, often drawing bright lines between “hemp” (legal) and “marijuana” (controlled), but the agency has offered little statutory clarity:
DEA has asserted through guidance letters and informal pronouncements that non-decarboxylated THCa (the acidic precursor to THC) should count toward total THC for controlled status. However, the underlying statutes reference only delta-9 THC concentration. Under Loper Bright, courts are less likely to defer to DEA’s interpretation unless it’s tightly anchored to the statute’s text and a robust administrative record (Canna Law Blog, Foley Hoag).
Federal circuit courts have recently rejected DEA’s attempts to control hemp-derived cannabinoids that meet Farm Bill definitions, underscoring that post-Chevron, courts are making their own calls on statutory interpretation—even where agencies argue for broad authority.
The distinction between “naturally derived” and “synthetic” cannabinoids—central to classifying substances as controlled under the CSA—has been handled by DEA via guidance, not clear regulations. With Loper Bright and Corner Post, affected businesses can mount fresh, text-based challenges to these interpretations.
In a post-Chevron world, both FDA and DEA will face a steeper burden when defending rules and guidance:
Businesses expanding into cannabis, hemp, and minor cannabinoid products should:
With upcoming rule proposals for CBD, synthetic cannabinoids, and rescheduling, operators should swiftly:
Thanks to Corner Post, even newly-formed businesses can contest old rules if those rules now harm them. Strategic challenges—particularly where agencies rely on ambiguous language—are more likely to garner favorable judicial review over blanket prohibitions or vague, broad rules.
2025–2026 is the most dynamic period cannabis and hemp have seen in decades, due to:
Post-Chevron, industry advocacy and well-supported challenges will play a crucial—perhaps decisive—role in the evolution of federal cannabis regulations.
Stay ahead of rapidly shifting federal cannabis and hemp policy. For the latest regulatory updates, strategic compliance insights, and tailored support, visit CannabisRegulations.ai.